$PBYI
PUMA BIOTECHNOLOGY, INC.

2020 Q3 Form 10-Q Financial Statement

#000156459020051427 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $50.75M $56.35M $53.92M
YoY Change -9.93% -10.02% 6.21%
Cost Of Revenue $9.943M $9.370M $9.317M
YoY Change 6.12% 3.56% 5.5%
Gross Profit $40.81M $46.98M $44.60M
YoY Change -13.13% -12.32% 6.36%
Gross Profit Margin 80.41% 83.37% 82.72%
Selling, General & Admin $29.60M $31.40M $33.53M
YoY Change -5.74% 10.17% -16.46%
% of Gross Profit 72.52% 66.84% 75.17%
Research & Development $23.34M $30.03M $36.86M
YoY Change -22.26% -17.42% -14.78%
% of Gross Profit 57.2% 63.91% 82.63%
Depreciation & Amortization $200.0K $200.0K $2.100M
YoY Change 0.0% -90.29% 11.7%
% of Gross Profit 0.49% 0.43% 4.71%
Operating Expenses $52.94M $70.80M $79.70M
YoY Change -25.22% -4.21% -13.57%
Operating Profit -$12.13M -$14.45M -$25.78M
YoY Change -16.04% 28.07% -37.8%
Interest Expense $3.627M $3.052M $4.448M
YoY Change 18.84% -12.78% 71.94%
% of Operating Profit
Other Income/Expense, Net -$19.33M -$2.437M -$11.64M
YoY Change 693.27% -16.54% 302.77%
Pretax Income -$31.46M -$16.89M -$37.42M
YoY Change 86.28% 18.94% -15.61%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$31.46M -$16.89M -$37.42M
YoY Change 86.34% 18.9% -15.59%
Net Earnings / Revenue -61.99% -29.96% -69.41%
Basic Earnings Per Share -$0.79 -$0.97
Diluted Earnings Per Share -$0.79 -$434.3K -$0.97
COMMON SHARES
Basic Shares Outstanding 39.70M 38.89M 38.65M
Diluted Shares Outstanding 39.70M 38.65M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.0M $110.4M $117.7M
YoY Change -1.27% -13.75% -12.49%
Cash & Equivalents $90.10M $58.90M $27.20M
Short-Term Investments $18.90M $51.50M $90.50M
Other Short-Term Assets $3.426M $322.0K $330.0K
YoY Change 963.98% -97.2% -97.18%
Inventory $3.100M $3.123M $3.260M
Prepaid Expenses $9.990M $11.01M
Receivables $24.60M $27.18M $25.35M
Other Receivables $5.900M $2.500M $0.00
Total Short-Term Assets $159.8M $151.1M $157.6M
YoY Change 5.76% -13.36% -7.34%
LONG-TERM ASSETS
Property, Plant & Equipment $2.659M $3.204M $3.432M
YoY Change -17.01% -23.71% -20.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.100M $16.10M $15.70M
YoY Change -62.11% 140.3% 127.54%
Total Long-Term Assets $101.9M $80.95M $82.25M
YoY Change 25.88% 43.72% 43.04%
TOTAL ASSETS
Total Short-Term Assets $159.8M $151.1M $157.6M
Total Long-Term Assets $101.9M $80.95M $82.25M
Total Assets $261.7M $232.0M $239.9M
YoY Change 12.78% 0.57% 5.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.50M $9.056M $15.07M
YoY Change 38.03% -44.66% -32.42%
Accrued Expenses $63.47M $76.77M $74.25M
YoY Change -17.32% 84.91% 80.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.714M
YoY Change
Total Short-Term Liabilities $118.2M $88.34M $91.66M
YoY Change 33.8% 52.63% 44.35%
LONG-TERM LIABILITIES
Long-Term Debt $91.71M $94.20M $93.40M
YoY Change -2.64% -22.21% -22.36%
Other Long-Term Liabilities $52.20M $32.30M $33.00M
YoY Change 61.61% 447.46% 500.0%
Total Long-Term Liabilities $91.71M $126.5M $126.4M
YoY Change -27.5% -0.39% 0.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $118.2M $88.34M $91.66M
Total Long-Term Liabilities $91.71M $126.5M $126.4M
Total Liabilities $262.1M $214.9M $218.1M
YoY Change 21.98% 16.26% 15.21%
SHAREHOLDERS EQUITY
Retained Earnings -$1.266B -$1.250B
YoY Change 8.12%
Common Stock $1.284B $1.271B
YoY Change 5.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$453.0K $17.18M $21.77M
YoY Change
Total Liabilities & Shareholders Equity $261.7M $232.0M $239.9M
YoY Change 12.78% 0.57% 5.39%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$31.46M -$16.89M -$37.42M
YoY Change 86.34% 18.9% -15.59%
Depreciation, Depletion And Amortization $200.0K $200.0K $2.100M
YoY Change 0.0% -90.29% 11.7%
Cash From Operating Activities $1.720M -$7.310M $44.25M
YoY Change -123.53% 0.69% -350.85%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.570M $38.98M $11.20M
YoY Change -106.59% -285.09% -129.02%
Cash From Investing Activities -$2.580M $38.98M $11.20M
YoY Change -106.62% -282.49% -128.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 70.00K -68.22M
YoY Change -28.57% -93.07% -192.44%
NET CHANGE
Cash From Operating Activities 1.720M -7.310M 44.25M
Cash From Investing Activities -2.580M 38.98M 11.20M
Cash From Financing Activities 50.00K 70.00K -68.22M
Net Change In Cash -810.0K 31.74M -12.77M
YoY Change -102.55% -214.96% -173.6%
FREE CASH FLOW
Cash From Operating Activities $1.720M -$7.310M $44.25M
Capital Expenditures -$10.00K $0.00 $0.00
Free Cash Flow $1.730M -$7.310M $44.25M
YoY Change -123.67% 5.03% -353.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M12D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
25493000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22643000
CY2019Q4 pbyi Post Marketing Commitment Liability Noncurrent
PostMarketingCommitmentLiabilityNoncurrent
9000000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
91714000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94962000
CY2019Q4 us-gaap Liabilities
Liabilities
217442000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
5714000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
90837000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1295033000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
128000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19332000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
25000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
8444000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39695444
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38893757
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39473691
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38675961
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16885000
us-gaap Net Income Loss
NetIncomeLoss
-64396000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-65000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
10000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-12000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31464000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16880000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45063000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64269000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
23403000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7565000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-453000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
21771000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12213000
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
76000
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
10000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
15000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16885000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
17180000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
17463000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27102000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-65000
us-gaap Net Income Loss
NetIncomeLoss
-45001000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-453000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
34306000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
45791000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1352000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-12000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
115000
us-gaap Net Income Loss
NetIncomeLoss
-64396000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
17180000
us-gaap Profit Loss
ProfitLoss
-45001000
us-gaap Profit Loss
ProfitLoss
-64396000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7085000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6178000
us-gaap Share Based Compensation
ShareBasedCompensation
27102000
us-gaap Share Based Compensation
ShareBasedCompensation
45791000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-54000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8047000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1759000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6409000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-26000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
498000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-4413000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2905000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3103000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1465000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6655000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11628000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
20951000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
30340000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
44000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
39000
pbyi Increase Decrease In Post Marketing Commitment Liability
IncreaseDecreaseInPostMarketingCommitmentLiability
-125000
pbyi Increase Decrease In Post Marketing Commitment Liability
IncreaseDecreaseInPostMarketingCommitmentLiability
9000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6408000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20810000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
24430000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
127072000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
28135000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
57033000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
104532000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22580000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5595000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
45000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1352000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
8444000
us-gaap Repayments Of Debt
RepaymentsOfDebt
80000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
7793000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5625000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-67066000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29033000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40661000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73210000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112738000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102243000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72077000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
30000000
us-gaap Interest Paid Net
InterestPaidNet
7021000
us-gaap Interest Paid Net
InterestPaidNet
9464000
us-gaap Income Taxes Paid
IncomeTaxesPaid
183000
pbyi Number Of Subsidiaries
NumberOfSubsidiaries
2
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-31500000
us-gaap Net Income Loss
NetIncomeLoss
-45000000.0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6400000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90100000
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
18900000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. </p>
CY2020Q3 pbyi Incremental Costs Expenses
IncrementalCostsExpenses
0
CY2019Q3 pbyi Incremental Costs Expenses
IncrementalCostsExpenses
0
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
12200000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
13200000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
93302000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93302000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
92840000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
62000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
92902000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September 30, 2020, were approximately $102.6 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $0 as an allowance for doubtful accounts as of September 30, 2020 and December 31, 2019.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.  </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company </span></p> <p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities.</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">The</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.</span></p>
CY2020Q3 pbyi Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
102600000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise
CY2020Q3 pbyi Average Incremental Borrowing Rate
AverageIncrementalBorrowingRate
0.109
CY2019 pbyi Reduction In Carrying Value Of Right Of Use Assets
ReductionInCarryingValueOfRightOfUseAssets
1200000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4300000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2000000.0
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
8000000.0
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
8000000.0
CY2020Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Nine
FiniteLivedIntangibleAssetsAmortizationExpenseYearNine
8000000.0
CY2020Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Eight
FiniteLivedIntangibleAssetsAmortizationExpenseYearEight
8000000.0
CY2020Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Seven
FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven
8000000.0
CY2020Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
8000000.0
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
8000000.0
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
8000000.0
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
8000000.0
CY2020Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Ten
FiniteLivedIntangibleAssetsAmortizationExpenseYearTen
2000000.0
CY2020Q3 pbyi Accounts Receivable Net Excluding License Revenue Receivable
AccountsReceivableNetExcludingLicenseRevenueReceivable
24637000
CY2019Q4 pbyi Accounts Receivable Net Excluding License Revenue Receivable
AccountsReceivableNetExcludingLicenseRevenueReceivable
26396000
CY2020Q3 pbyi License Revenue Receivable
LicenseRevenueReceivable
2500000
CY2019Q4 pbyi License Revenue Receivable
LicenseRevenueReceivable
2500000
CY2020Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
27137000
CY2019Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
28896000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8025000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2820000
CY2020Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
10845000
CY2020Q3 pbyi Deposit For Manufacturing Costs Current
DepositForManufacturingCostsCurrent
3376000
CY2020Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
50000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3426000
pbyi Fixed Lease Expense
FixedLeaseExpense
3500000
us-gaap Variable Lease Cost
VariableLeaseCost
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
4194000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1312000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5365000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5483000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5631000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5805000
CY2020Q3 pbyi Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
7491000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31087000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7751000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23336000
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
100000
us-gaap Sublease Income
SubleaseIncome
300000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
115000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
467000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
481000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
495000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
510000
CY2020Q3 pbyi Lessor Operating Lease Payments To Be Received After Year Four
LessorOperatingLeasePaymentsToBeReceivedAfterYearFour
659000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2727000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8691000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9163000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6032000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5859000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2659000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3304000
CY2020Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
700000
CY2020Q3 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
90000000
CY2019Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
50000000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13856000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9539000
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
76144000
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
40461000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4300000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y6M
CY2020Q3 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
22569000
CY2019Q4 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
31350000
CY2020Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8002000
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8866000
CY2020Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
3510000
CY2019Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
8502000
CY2020Q3 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
13368000
CY2019Q4 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
7978000
CY2020Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5968000
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1618000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4688000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4138000
CY2020Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1531000
CY2019Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2546000
CY2020Q3 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
2430000
CY2019Q4 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
1775000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
545000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
266000
CY2020Q3 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
494000
CY2019Q4 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
869000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
366000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1122000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63471000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69030000
CY2020Q3 pbyi Accrued Legal Verdict Expense Non Current
AccruedLegalVerdictExpenseNonCurrent
24822000
CY2020Q3 pbyi Accrued Clinical Research Organization Services Noncurrent
AccruedClinicalResearchOrganizationServicesNoncurrent
542000
CY2020Q3 pbyi Employee Related Liabilities Noncurrent
EmployeeRelatedLiabilitiesNoncurrent
92000
CY2020Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
37000
CY2020Q3 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
25493000
CY2020Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
88964000
CY2019Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
69030000
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2024-06-01
CY2020Q3 pbyi Accretion Of Final Interest Payment
AccretionOfFinalInterestPayment
2951000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
5714000
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
5523000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
91714000
CY2020Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
8668000
CY2019Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
8668000
CY2020Q3 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
3145000
CY2019Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
1701000
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
5523000
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6967000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1400000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
505627
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
531112
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2021-10-04
CY2020Q3 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
7565000
CY2019Q3 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
12213000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
27102000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
45791000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5042325
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
82.42
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1951000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700853
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.03
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
80000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
551597
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
92.49
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5179581
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
71.73
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3351000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1008221
CY2020Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
12.10
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4171360
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
86.14
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2138000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
439194
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
19.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700853
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
131826
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
34.03
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.42
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1200000
CY2020Q3 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000
pbyi Percentage Of Unpaid Portion Of Milestone Payments Interest Rate
PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate
0.0625

Files In Submission

Name View Source Status
0001564590-20-051427-index-headers.html Edgar Link pending
0001564590-20-051427-index.html Edgar Link pending
0001564590-20-051427.txt Edgar Link pending
0001564590-20-051427-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pbyi-10q_20200930.htm Edgar Link pending
pbyi-10q_20200930_htm.xml Edgar Link completed
pbyi-20200930.xsd Edgar Link pending
pbyi-20200930_cal.xml Edgar Link unprocessable
pbyi-20200930_def.xml Edgar Link unprocessable
pbyi-20200930_lab.xml Edgar Link unprocessable
pbyi-20200930_pre.xml Edgar Link unprocessable
pbyi-ex311_12.htm Edgar Link pending
pbyi-ex312_10.htm Edgar Link pending
pbyi-ex321_11.htm Edgar Link pending
pbyi-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending